PRL and breast carcinoma: Number of patients and breast cancer events for high prolactin-increasing antipsychotic users and non-prolactin-increasing antipsychotic users, we report population size, total exposure time, outcome events and minimal detectable risk ratio (MDRR) for the PS 1-1 matching analysis.